Assimakis Komninos
White & Case (Brussels)
Lawyer (Partner)
Dr Assimakis Komninos is a Partner at the Brussels office of White & Case. Between 2009 and 2011 he was a Commissioner and Member of the Board of the Hellenic Competition Commission (HCC). He has acted before the European Court of Justice in Syfait v. GlaxoSmithKline and Lélos v. GlaxoSmithKline (parallel trade of pharmaceuticals - abuse of dominance), and in GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - Article 101). He was also involved before the EU General Court in Microsoft v. Commission (compulsory licensing of interoperability information), GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - application of Article 101), Chalkor Metal Works v. Commission (copper plumbing tubes) and Public Power Corporation v. Commission (Greek lignites). Dr Komninos successfully represented Aegean Airlines as lead counsel in Aegean/Olympic II, which resulted in the European Commission clearing the deal two years after it had previously blocked it. He has also represented or advised clients in proceedings before the Albanian, Cypriot, French, Greek, Kosovo and Romanian competition authorities and Belgian, Bulgarian, Cypriot, French, Greek, Latvian and Spanish appellate courts, and has particular expertise in arbitration cases involving EU and national competition issues, and in private antitrust litigation cases in national courts. Dr Komninos is currently a visiting fellow of the Centre for Law and Governance in Europe at University College London (UCL), where he teaches EU competition law, and a senior associate fellow of the Institute for European Studies (IES) at the Vrije Universiteit Brussels (VUB).
Distinctions
Nominee, 2019 Antitrust Writing Awards : Business, Unilateral Conduct
Nominee, 2019 Antitrust Writing Awards : Academic, Unilateral Conduct
Nominee, 2018 Antitrust Writing Awards : Business, Unilateral Conduct
Nominee, 2017 Antitrust Writing Awards : Business, Cross-Border Issues
Nominee, 2016 Antitrust Writing Awards : Business, Procedure
Nominee, 2015 Antitrust Writing Awards : Business, Mergers
Winner, 2014 Antitrust Writing Awards : Business, Private Enforcement
Nominee, 2013 Antitrust Writing Awards : Business, General Antitrust
Auteurs associés
Ian Forrester
General Court of the European Union (Luxembourg)
Patrick Rey
Institut d’économie Industrielle (IDEI)
Pascal Berghe
European Commission (Brussels)
José Luis Buendia Sierra
Garrigues (Brussels)
Robert Kovar
University of Strasbourg
Ioannis Lianos
University College London
Francesco Rosati
RBB Economics (Brussels)
1506 | Conférences
Articles
17384 Bulletin
83
On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions in the market by pricing their epilepsy drug unfairly. Among other (...)
431
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The CMA Remicade decision : discount schemes and abuse of dominance – effects matter !* Summary On 14 March 2019, the UK Competition and Markets Authority (CMA) (...)
528
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. EU Court confirms the need for transparency and full disclosure of economic analyses in EU merger cases (UPS/TNT)* On 16 January 2019, the Court of Justice of (...)
426
I. Introduction In the last couple of years, there has been a trend for antitrust watchdogs around the world to investigate excessive pricing, especially in the phar- maceutical sector. Last year, the European Commission opened its first investigation into excessive pricing in the (...)
630
This article has been nominated for the 2018 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On 6 September 2017, the Court of Justice of the European Union ("CJEU" or "Court") essentially held in Intel that the European Commission ("Commission") cannot (...)
173
1. Background In its decision dated 23/6/2015 the Cypriot Commission for the Protection of Competition (the “CPC”) held that the operator of the Larnaca and Paphos international Airports in Cyprus, Hermes Airports Ltd, (hereafter referred as “Hermes”) violated Section 6(1)(a) of the Cyprus Law on (...)
736
On 5 March 2015, the European Court of Justice (CoJ) handed down its judgment in Versalis , concerning the increasing of fines for antitrust infringements where a company is found to be a repeat offender. The judgment raises important questions about the respect for the rights of defence in EU (...)
184
Class Actions : Now in Belgium*Class actions are a hot topic in Europe, and elsewhere. Various European countries have introduced, or are in the process of introducing, class action mechanisms. At the European Union level a similar development is noticeable, with proposals both in the field of (...)
174
This article has been nominated for the 2014 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Summary On 11 June 2013, the European Commission (“Commission”) adopted a proposal for a directive on how citizens and companies can bring damages claims under EU (...)
488
White Paper on damages actions for breach of EC antitrust rules. What Does It Mean For Business ? The White Paper brushes aside fears expressed in the business world and among practitioners about the import into Europe of a US-style mixture of aggressive class actions and treble damages and (...)
3074
On August 2005, a new Act was passed amending the Greek Competition Act n° 703 of 1977, which itself has been amended in the past on numerous occasions. The main objective of Law 3373/2005 was to reshuffle Greek competition law and essentially to respond to the new context of competition law (...)
10457
On 31 May 2005 the European Court of Justice (ECJ) delivered its judgment in Case C-53/03, Syfait and others v. GlaxoSmithKline AEVE and GlaxoSmithKline plc (“Syfait”), which raises the question of whether a dominant pharmaceutical undertaking is under a duty to supply unlimited quantities of (...)
32487 Revue
847
La première table-ronde de la conférence qui s’est tenue le 13 mai 2014 à Paris sur le thème de la réparation des dommages concurrentiels était dédiée aux dommages concurrentiels dans les systèmes juridiques étrangers. Michele CARPAGNANO Professeur, Université de Trente Codirecteur, Osservatorio (...)
1557
L’existence et l’application de la soi-disant "exception d’efficience" de l’article 102 du TFUE ont fait l’objet de grandes discussions ces dernières années. Le document d’orientation de 2009 a donné un nouvel essor à la notion. Les articles réunis dans ce tendances donnent le point de vue de l’Union (...)
2797
La Commission européenne voit dans le « test de l’opérateur aussi efficace » un test général applicable aux stratégies tarifaires des entreprises dominantes. Les contributions à ce Tendances présentent ce test dans les différents domaines où l’on le rencontre. Le sujet a d’autant plus d’intérêt que la (...)
1612
1. Makis, you have been a Commissioner and Member of the Board of the Hellenic Competition Commission (HCC) for a year and a half, having left Brussels and an international law firm. Do you miss the life of a practitioner in Brussels ? 2. Can you describe your work at the HCC ? 3. Greece has (...)
6811
What does the Commission’s recent Communication on enforcement of Article 82 EC mean for companies ? Does it make enforcement more predictable ? Does the greater use of economic concepts reduce the risk that intense competition on the merits by the part of a dominant firm will be considered (...)
7186
Cette deuxième table-ronde du colloque "Quel avenir pour les restrictions verticales ?" (Paris, 23 mai 2008) est dédiée aux questions posées par les importations parallèles. Les récentes affaires en matère de produits pharmaceutiques ont souligné l’importance des enjeux et la difficulté de (...)
6125
The European Commission has published early April 2008 its White Paper on damages actions for antitrust violations. The White Paper makes a number of important specific proposals with the aim to facilitate civil antitrust claims for damages in Europe that will certainly create a lot of (...)
5552
La Commission européenne tend de plus en plus à faire référence aux objectifs de l’Agenda de Lisbonne, et plus particulièrement à la compétitivité des entreprises européennes dans ses discours sur la politique communautaire de concurrence. L’Agenda de Lisbonne est présenté comme l’objectif prioritaire de (...)
Livres
Prix
230€00
Ian Forrester - A Scot Without Borders Liber Amicorum Vol. II
This two-volume Liber amicorum is a collection of tributes to Ian Forrester’s outstanding career and articles signed by prominent academics and practitioners around the world on the most current (...)
Date
1er décembre 2015
Prix
230€00
Prix
220€00
Ian Forrester - A Scot Without Borders Liber Amicorum Vol. I
This two-volume Liber amicorum is a collection of tributes to Ian Forrester’s outstanding career and articles signed by prominent academics and practitioners around the world on the most current (...)
Date
23 septembre 2015
Prix
220€00
2013 Competition Case Law Digest - A Synthesis of EU and National Leading Cases
The purpose of this book is to compare and contrast EU competition case law with European Members States competition case law, and Members States competition case law with each other. To the best (...)
Date
12 décembre 2012
